Health plans make substantial investments in retrieving and reviewing medical records every year. But siloed review functions have traditionally meant duplicative retrieval costs and review time. Risk adjustment, quality, and provider engagement teams need different information at different times, so duplicated efforts and expenses were an accepted cost of doing business in Medicare Advantage.
Today, AI technologies trained on clinical documentation are giving Medicare Advantage organizations a new way forward.
From fractional focus to continuous intelligence
Risk adjustment teams conduct retrospective chart reviews to capture additional value hidden in their members’ charts. But traditional retrospective coding only captures a fraction of this value in the form of incremental coding opportunities.
Forward-thinking leaders are asking an essential question: what happens to the clinical intelligence uncovered during a retrospective review that could inform prospective care, quality gap closure, and future validation exercises?
Consider a chronic condition documented in a prior-year specialist note that is missing from administrative claims data. While a standard vendor might flag this solely for a retrospective add for the prior year, an advanced chart intelligence partner preserves the full context—including dates of service, specific provider attestation, and direct citation of clinical evidence. This transforms a static chart retrieval into actionable prospective intelligence, giving clinical and provider engagement teams a valuable starting point: verifying whether a historical condition has been re-evaluated during a current-year encounter or requires targeted prospective clinical follow-up.
Modern AI-enabled chart review platforms can detect clinical evidence with a high rate of recall. When combined with human-in-the-loop evaluation of the evidence and tools for preserving that clinical judgment, they can also deliver value that extends beyond the coding file, giving plans the ability to establish an integrated system of record that serves multiple program goals simultaneously.
For risk adjustment executives, selecting the right partner offers clear operational advantages: streamlined chart pursuit and traceable evidence behind every clinical insight.
Key capabilities to demand in vendor evaluation
While claims and pharmacy data highlight reported diagnoses and prescription patterns, medical records supply essential context: provider notes, treatment status, and longitudinal trends. Building a more effective prospective program requires looking beyond raw suspect counts to consider how deeply a vendor enriches administrative signals with traceable clinical documentation.
A risk adjustment vendor that preserves and builds clinical intelligence can deliver structured clinical outputs that automatically categorize findings based on necessary operational actions. When assessing vendor deliverables, confirm that their platform categorizes findings into distinct actionable streams:
- Defensible retrospective additions: Validated diagnosis additions supported by exact chart evidence and meeting all CMS risk adjustment documentation and submission requirements.
- Prospective evaluation opportunities: Historical chronic conditions needing current-year evaluation that have not yet appeared in encounter data.
- Clinical clarification candidates: Ambiguous or unconfirmed documentation that cannot support submission as written, flagged for compliant follow-up at the next encounter.
- Suppressed or contradicted findings: Resolved or ruled-out conditions filtered out to eliminate unnecessary provider abrasion and redundant outreach. When a contradicted finding involves a diagnosis that was already submitted, it should be routed for deletion.
These structured distinctions allow risk adjustment teams to focus on meaningful clinical gaps rather than wading through unstructured suspect lists.
By choosing a vendor that provides an open, evidence-backed chart repository, health plans ensure that every retrieved record serves multiple initiatives. Prospective teams can easily leverage prior review findings, check current-year progress, and limit new chart requests strictly to unverified conditions.
For provider networks, this targeted methodology means fewer duplicate record inquiries and clearer clinical queries. For health plan teams, it streamlines operations and reduces reconciliation friction.
Measuring metrics that matter
Evaluating vendors solely on suspect volume or initial RAF yield relies on an outdated rubric. A large suspect list often reflects poor filtering rather than high-value intelligence. When grading risk adjustment partners, executives should measure performance against four essential criteria:
- Clinical finding precision: The share of flagged findings that hold up on clinical review, with accurate evidence, dates of service, and provider attestation.
- Workflow integration efficiency: The ability of internal teams and providers to interpret and act on findings without manual chart re-review.
- Resolution rate: Percentage of suspect leads successfully evaluated, confirmed, or ruled out in clinical practice.
- Resource optimization: Reduction in duplicate retrieval costs, review hours, and unnecessary provider outreach.
In a mature program, ruling out an incorrect suspect is a valuable outcome that prevents unnecessary provider friction and preserves operational efficiency.
Selecting a strategic risk adjustment partner
Transitioning from basic retrospective coding to integrated chart intelligence transforms chart retrieval into an ongoing strategic asset.
To guide your next vendor evaluation, focus on three essential questions:
- What depth of evidence and clinical context does the vendor deliver alongside coding outputs?
- How seamlessly do their outputs feed into prospective care workflows and audit preparation?
- How does the vendor measure long-term value beyond simple suspect counts?
By demanding clinical transparency, actionable context, and robust audit defensibility, health plan leaders can select a vendor partner that maximizes return on chart investment across every program cycle.
To explore how Charta’s AI-enabled chart intelligence platform enhances accuracy and connects retrospective review to prospective success, schedule a demo with our clinical solutions team today.